My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
CTI BioPharma Corp. (CTIC)
NASDAQ:CTIC
CTIC nasdaq
United States
CTI BioPharma

CTI BioPharma Stock Analysis & Ratings

CTI BioPharma Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The CTI BioPharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

CTIC

CTIC Stock Stats

Previous Close$2.66
Open$2.58
Bid2.72 x 80
Ask2.83 x 100
Today’s Range$2.47 - $2.86
52-Week Range$2.15 - $4.13
Volume5.32M
Average Volume900.33K
Market Cap$257.20M
Beta0.68
P/E Ratio-2.8
EPS-0.90
Earnings DateMar 16, 2022

Company Description

CTI BioPharma Corp.

CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Sector
Healthcare
Industry
Biotechnology
CEO
Adam R. Craig
Employees
23
ISIN
US12648L6011
Address
3101 Western Avenue, Seattle, WA, 98121, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

CTIC FAQ

What was CTI BioPharma’s price range in the past 12 months?
CTI BioPharma lowest stock price was $2.15 and its highest was $4.13 in the past 12 months.
    What is CTI BioPharma’s market cap?
    CTI BioPharma’s market cap is $257.20M.
      What is CTI BioPharma’s price target?
      The average price target for CTI BioPharma is $5.40. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.20 ,the lowest forecast is $4.00. The average price target represents 103.01% Increase from the current price of $2.66.
        What do analysts say about CTI BioPharma?
        CTI BioPharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is CTI BioPharma’s upcoming earnings report date?
          CTI BioPharma’s upcoming earnings report date is Mar 16, 2022 which is in 106 days.
            How were CTI BioPharma’s earnings last quarter?
            CTI BioPharma released its earnings results on Nov 08, 2021. The company reported -$0.258 earnings per share for the quarter, beating the consensus estimate of -$0.263 by $0.005.
              Is CTI BioPharma overvalued?
              According to Wall Street analysts CTI BioPharma’s price is currently Undervalued.
                Does CTI BioPharma pay dividends?
                CTI BioPharma does not currently pay dividends.
                What is CTI BioPharma’s EPS estimate?
                CTI BioPharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does CTI BioPharma have?
                CTI BioPharma has 96,690,000 shares outstanding.
                  What happened to CTI BioPharma’s price movement after its last earnings report?
                  CTI BioPharma reported an EPS of -$0.258 in its last earnings report, beating expectations of -$0.263. Following the earnings report the stock price went down -2.151%.
                    Which hedge fund is a major shareholder of CTI BioPharma?
                    Among the largest hedge funds holding CTI BioPharma’s share is Consonance Capital. It holds CTI BioPharma’s shares valued at N/A.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis